Sio Gene Receives US Food and Drug Administration's Fast Track Designation for GM2 Gangliosidosis Gene Therapy-- Sio Gene Therapies said Monday the US Food and Drug Administration granted fast track designation to its investigational gene therapy AXO-AAV-GM2 for the treatment of early infantile, late...